Videos

Bose explains her research on vaping among millennial adults who may be at peak lung health, describing the diverse landscape of vaping devices and products.

In this interview, nerandomilast’s safety profile in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is highlighted.

Attaway reviews data demonstrating the potential benefit of a subspecialty clinic for overcoming current diagnostic and treatment-related challenges for sarcopenia in COPD.

This interview highlights phase 3 trial data on nerandomilast’s use in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

In this interview, Chalmers highlights the implications of his team’s subgroup analysis findings in the ASPEN trial, as well as unmet needs for non-cystic fibrosis bronchiectasis.

Discover innovative treatments for plaque psoriasis that cater to diverse skin tones, offering effective relief without the risk of discoloration.

Trief and MD candidate Justin Cheong physically peeled the Haab’s striae from a patient’s eye, allowing for better adherence and maintenance of the DSEK graft.

Jain discussed Rejoyn, the FDA-approved digital therapeutic app that enhances major depressive disorder treatment with engaging brain training and mindfulness exercises.

Murphy discusses innovative surgical techniques for managing glaucoma and cataracts, emphasizing minimally invasive approaches and the future of ophthalmology.

This special episode of Lungcast features Harold P. Wimmer, CEO of the ALA, and Francesca Polverino, MD, PhD, an ALA spokesperson.

Gerard Criner, MD, reviews findings from a secondary analysis of the phase 3 MATINEE trial of mepolizumab and looks ahead to the potential significance of the drug, if approved.

In her interview at ATS, Willen further described elements highlighted in her presentation on new treatments for sickle cell disease.

This interview at ATS 2025 features a discussion of a ‘Pediatric Year in Review’ presentation on new therapies for sickle cell disease.

Breazzano presented a video of a surgery repositioning an Akreos AO60 lens, highlighting the complicated nature of the procedure and its planning.

Abramson discusses the potential benefits and limitations of treatment methods for Coats’ disease and further discusses the genetic component of its pathology.

This interview highlights the long-term, late-breaking results of the A DUE trial’s 24-month open-label extension on macitentan and tadalafil for PAH.

Criner reviews findings from AIRFLOW-3 and describes the subgroup of targeted lung denervation treatment responders being targeted in AIRFLOW-4.

In this episode, hosts explore real-world data on Beta Bionics' iLet automated insulin delivery system for diabetes management.

Attaway describes the importance of screening for and treating sarcopenia in patients with COPD and clinical gaps that complicate this process.

In this interview at ATS 2025, Arthur Reingold, MD, highlights the role of pulmonologists and other health care providers in combatting vaccine misinformation.

Marchetti explains the benefits of assessing RV/TLC rather than absolute RV to determine the efficacy of BLVR in patients with emphysema and hyperinflation.

Shultz discusses the impact of lotilaner ophthalmic solution 0.25% to treat active Demodex blepharitis in patients with meibomian gland dysfunction.

Abramson's presented operation indicates that Coats disease can manifest bilaterally and is potentially caused by multiple independent genes.

Williams discusses her takeaways from the 2025 Envision conference and her expectations for the future of both ophthalmology and its practitioners.

This interview at ATS 2025 highlights the talk given by Grace Lee, MD, MPH, regarding the policy side of public health concerns over widespread immunization.

Phase 3 BATURA data reveal a 47% reduction in the risk of severe exacerbations in mild asthma with albuterol/budesonide (Airsupra) versus albuterol alone.

At 2025 New Wave Dermatology, HCPLive spoke with Miranti on treating the 4 pillars of pathogenesis, including sebum production, inflammation, and more.

In this ATS 2025 interview, Arthur Reingold, MD, was asked about the effects of the COVID-19 pandemic on immunization rates as well as pulmonologists’ role.